•The Year Ahead Pharm Exec presents its annual outlook on what to expect in 2011—boom, bust, or just muddling through? Key trends impacting the business model combined with contributions from a dozen thought leaders—including members of the Pharm Exec editorial advisory board—will drive home the message that a heady dose of change won't bring relief for the complacent "sugar pill" crowd.

•Building Biotech: Small Caps Share the San Diego Sunshine
Pharm Exec makes a visit to the biotech startup community in San Diego and finds a group cautiously optimistic about prospects for productive relationships with Pfizer, Merck, and other Big Pharma companies with deep pockets.

•Q&A with Francis Collins
Francis Collins, head of the National Institutes of Health, sits down with Pharm Exec to discuss the future of the world's largest government funder of basic medical research in an era of fiscal retrenchment.

COLUMNS

• Strategy: Amgen Makes the Mark on Clinical Trials in Emerging Markets
A team from Amgen presents a novel approach to leveraging the advantages of managing clinical trial programs in booming emerging markets

• Adherence: The Adherence Equation: The Code is Cracked
Andrea LaFountain’s third installment in her series

BONUS DISTRIBUTION

• CBI EVENTS
4th Annual Forum on Oncology Commercialization Strategies
8th Annual Pharmaceutical Compliance Congress